LIXTE Biotechnology Holdings (NASDAQ: LIXT) is advancing its clinical-stage pipeline with LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A), as a novel approach to cancer treatment. Rather than replacing established therapies, LB-100 is designed to enhance their effectiveness by stimulating cell-cycle progression and interfering with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy.
LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. The compound’s ability to inhibit PP2A is central to its mechanism of action, as PP2A is a key regulator of cell growth and division. By blocking PP2A, LB-100 may sensitize cancer cells to DNA-damaging agents and immune-based treatments.
According to a recent article highlighting LIXTE’s progress, the company spent 2025 expanding its presence across multiple segments of oncology innovation. The article notes that LB-100 is part of a pioneering effort in an entirely new field of cancer biology—activation lethality—that is advancing a new treatment paradigm. LIXTE’s approach is supported by a comprehensive patent portfolio and extensive preclinical data, which can be accessed at www.lixte.com.
LIXTE has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. The company’s proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer, with the goal of improving outcomes for patients who have limited treatment options.
The implications of this announcement are significant for the oncology field, as LB-100 represents a potential strategy to enhance the efficacy of existing therapies without introducing entirely new toxicities. By targeting PP2A, LB-100 may address a fundamental vulnerability in cancer cells, offering a complementary approach to current standards of care. For investors and stakeholders, LIXTE’s progress underscores the potential of first-in-class agents to reshape treatment landscapes, particularly in hard-to-treat solid tumors.
For more information on LIXTE and its pipeline, visit the company’s newsroom at https://ibn.fm/LIXT.
